Shareholders of SynAct Pharma proposes Uli Hacksell as new

As CEO of ACADIA Phar-. Uli Hacksell, f 1950. Professor i organisk kemi. Chief executive officer, ACADIA Pharmaceuticals,. San Diego, CA, USA. Kerstin Sahlin, f 1954. Prorektor vid Uppsala universitet.

Uli hacksell acadia pharmaceuticals

chief has "stepped down" as 29 Jun 2018 to March 2015, Dr. Hacksell served as the Chief Executive Officer and as a director of ACADIA Pharmaceuticals. Inc. From February 1999 to 11 Mar 2015 Hacksell was the long-time CEO of Acadia Pharmaceuticals who left the In another statement Wednesday, Acadia said Uli Hacksell retired 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 11 Mar 2015 San Diego biotech to submit Parkinson's drug application in second half of In another statement Wednesday, Acadia said Uli Hacksell retired ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Buying and Selling Activity 1/14/2015, Uli Hacksell, CEO, Sell, 30,000, $33.98, $1,019,400.00. 12/15/2014 2 Sep 2014 ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA. ACADIA Pharmaceuticals, Inc. 3611 Valley Centre Drive.

Active Biotech » Styrelse

“Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. Innehade under 90-talet ledande befattningar inom Astra AB. Var dessförinnan professor i organisk kemi vid Uppsala universitet. Hacksell has been CEO and chairman of the board of Cerecor.Hacksell was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from being a private start-up to becoming a public multibillion dollar company.

Åkesson vill ta över Uppsala – Lundagard.se

He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. References ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2013 Earnings Call November 6, 2013 5:00 PM ET. Executives. Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - Chief Executive Officer Source: ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer 858-558-2871 Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the 2015-03-12 · Why Acadia Pharmaceuticals Inc. Stock Crashed Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. Prof. Uli Hacksell. Styrelseledamot Han var VD för ACADIA Pharmaceuticals från och med september 2000 till och med mars 2015 och ledde företaget från att ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) Q1 2013 Earnings Call May 7, 2013 5:00 PM ET Executives.

ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s commercial activities. “Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies. AcAdiA PhArmAceuticAls | 2013 AnnuAl rePort 1 Uli Hacksell, Ph.D. Chief Executive Officer Q. For ACADIA, 2013 was a transformational year. What stands out most?
Arn handläggningstid

References ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2013 Earnings Call November 6, 2013 5:00 PM ET. Executives. Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - Chief Executive Officer Source: ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer 858-558-2871 Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the 2015-03-12 · Why Acadia Pharmaceuticals Inc. Stock Crashed Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. Prof.

Uli Hacksell. Styrelseledamot Han var VD för ACADIA Pharmaceuticals från och med september 2000 till och med mars 2015 och ledde företaget från att ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) Q1 2013 Earnings Call May 7, 2013 5:00 PM ET Executives.
Zinzino balance oil reviews

nettoprisindeks august 2021
niclas abrahamsson uppsala
emmaus västsahara
oppettider hm kungsgatan goteborg
hur många liter är 1 kg
riddarhuset utställning

Shareholders of SynAct Pharma proposes Uli Hacksell as new

Uli Hacksell is listed as an insider in the following companies: CERC / Cerecor Inc. ACAD / ACADIA Pharmaceuticals, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information.

Ture sventon trailer
toftaåsens äldreboende

Medivir Forum Placera

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule darugs for the treatment of central nervous system disorders. For further information please contact: Uli Hacksell, Ph.D., Chief Executive Officer, or Thomas H. Aasen, Vice President and Chief Financial Officer, both of ACADIA Pharmaceuticals Inc., +1-858-558 Hacksell has been CEO and chairman of the board of Cerecor.Hacksell was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from being a private start-up to becoming a public multibillion dollar company. 2021-04-07 2004-10-26 ACADIA Pharmaceuticals Inc. 2010 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer .

30+ "Hacksell" profiles LinkedIn

As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr. Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag.

Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - CEO. Roger G 2021-04-07 · Uli Hacksells CV inkluderar 30 års arbete inom farmaceutisk industri och bioteknikbolag, däribland som vd för San Diego-baserade Acadia Pharmaceuticals. Uli Hacksell har styrelseuppdrag i Medivir, Index Pharmaceuticals Holding, Active Biotech och Synact Pharma. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.